Search

Your search keyword '"Oreglia Jacopo Andrea"' showing total 35 results
Start Over Author "Oreglia Jacopo Andrea"
35 results on '"Oreglia Jacopo Andrea"'

1. Reply to SGLT-2 inhibitors: Post-infarction interventional effects

Author

Pasquale Paolisso, Luca Bergamaschi, Felice Gragnano, Emanuele Gallinoro, Arturo Cesaro, Celestino Sardu, Niya Mileva, Alberto Foà, Matteo Armillotta, Angelo Sansonetti, Sara Amicone, Andrea Impellizzeri, Giuseppe Esposito, Nuccia Morici, Oreglia Jacopo Andrea, Gianni Casella, Ciro Mauro, Dobrin Vassilev, Nazzareno Galie, Gaetano Santulli, Raffaele Marfella, Paolo Calabrò, Emanuele Barbato, and Carmine Pizzi

Subjects
Therapeutics. Pharmacology, RM1-950
Published
2023
Full Text
View/download PDF

2. SGLT2-inhibitors in diabetic patients with severe aortic stenosis and cardiac damage undergoing transcatheter aortic valve implantation (TAVI)

Author

Paolisso, Pasquale, Belmonte, Marta, Gallinoro, Emanuele, Scarsini, Roberto, Bergamaschi, Luca, Portolan, Leonardo, Armillotta, Matteo, Esposito, Giuseppe, Moscarella, Elisabetta, Benfari, Giovanni, Montalto, Claudio, Shumkova, Monika, de Oliveira, Elayne Kelen, Angeli, Francesco, Orzalkiewicz, Mateusz, Fabroni, Margherita, Baydaroglu, Nurcan, Munafò, Andrea Raffaele, D’Atri, Daniele Oreste, Casenghi, Matteo, Scisciola, Lucia, Barbieri, Michelangela, Marfella, Raffaele, Gragnano, Felice, Conte, Edoardo, Pellegrini, Dario, Ielasi, Alfonso, Andreini, Daniele, Penicka, Martin, Oreglia, Jacopo Andrea, Calabrò, Paolo, Bartorelli, Antonio, Pizzi, Carmine, Palmerini, Tullio, Vanderheyden, Marc, Saia, Francesco, Ribichini, Flavio, and Barbato, Emanuele

Published
2024
Full Text
View/download PDF

3. Coronary Lithotripsy as Elective or Bail-Out Strategy After Rotational Atherectomy in the Rota-Shock Registry

Author

Sardella, Gennaro, Stefanini, Giulio, Leone, Pier Pasquale, Boccuzzi, Giacomo, Fovero, Natalia Tovar, Van Mieghem, Nicolas, Giacchi, Giuseppe, Escaned, Javier, Fineschi, Massimo, Testa, Luca, Valenti, Renato, Di Mario, Carlo, Briguori, Carlo, Cortese, Bernardo, Ribichini, Flavio, Oreglia, Jacopo Andrea, Colombo, Antonio, Sangiorgi, Giuseppe, Barbato, Emanuele, Sonck, Jeroen, Ugo, Fabrizio, Trani, Carlo, Castriota, Fausto, Paggi, Anita, Porto, Italo, Tomai, Fabrizio, and Mancone, Massimo

Published
2023
Full Text
View/download PDF

4. List of contributors

Author

Abi Rafeh, Nidal, primary, Agostoni, Pierfrancesco, additional, Akyuz, Sukru, additional, Alaswad, Khaldoon, additional, Ali, Ziad A., additional, Allana, Salman S., additional, Alraies, Chadi, additional, Araya, Mario, additional, Avran, Alexandre, additional, Azzalini, Lorenzo, additional, Babunashvili, Avtandil, additional, Banerjee, Subhash, additional, Bangalore, Sripal, additional, Bayani, Baktash, additional, Behnes, Michael, additional, Bhindi, Ravinay, additional, Boudou, Nicolas, additional, Božinović, Nenad Ž., additional, Bryniarski, Leszek, additional, Bufe, Alexander, additional, Buller, Christopher E., additional, Burke, M. Nicholas, additional, Cardoso, Pedro Pinto, additional, Carlino, Mauro, additional, Cavalcante, Joao L., additional, Chami, Tarek, additional, Chandwaney, Raj H., additional, Charitakis, Konstantinos, additional, Cheng, Victor Y., additional, Choi, James W., additional, Christiansen, Evald Høj, additional, Chugh, Yashasvi, additional, Colombo, Antonio, additional, Cosgrove, Claudia, additional, Croce, Kevin, additional, Daggubati, Ramesh, additional, Damas de los Santos, Félix, additional, Dautov, Rustem, additional, Davies, Rhian E., additional, de Martini, Tony, additional, Denktas, Ali E., additional, Dens, Joseph, additional, di Mario, Carlo, additional, Diletti, Roberto, additional, Dimitriadis, Zisis, additional, Doshi, Darshan, additional, Doshi, Parag, additional, Dou, Kefei, additional, Egred, Mohaned, additional, Elbarouni, Basem, additional, ElGuindy, Ahmed M., additional, Elhadidy, Amr, additional, Ellis, Stephen, additional, Escaned, Javier, additional, Fasseas, Panayotis, additional, Forouzandeh, Farshad, additional, Furkalo, Sergey, additional, Gagnor, Andrea, additional, Galassi, Alfredo R., additional, Gallino, Robert, additional, Garbo, Roberto, additional, Garcia, Santiago, additional, Gasparini, Gabriele, additional, Ge, Junbo, additional, Ge, Lei, additional, Goel, Pravin Kumar, additional, Goktekin, Omer, additional, Gonzalo, Nieves, additional, Gorgulu, Sevket, additional, Grancini, Luca, additional, Grantham, J. Aaron, additional, Guddeti, Raviteja, additional, Haddad, Elias V., additional, Hall, Allison B., additional, Hall, Jack J., additional, Halligan, Sean, additional, Hanna Quesada, Franklin Leonardo, additional, Hanratty, Colm, additional, Harb, Stefan, additional, Harding, Scott A., additional, Hatem, Raja, additional, Hildick-Smith, David, additional, Hill, Jonathan M., additional, Hirai, Taishi, additional, Iannaccone, Mario, additional, Jaber, Wissam, additional, Jaffer, Farouc A., additional, Jang, Yangsoo, additional, Jefferson, Brian K., additional, Jeremias, Allen, additional, Jussila, Risto, additional, Kakouros, Nikolaos, additional, Kalnins, Artis, additional, Kalra, Sanjog, additional, Kalyanasundaram, Arun, additional, Kandzari, David E., additional, Kao, Hsien-Li, additional, Karacsonyi, Judit, additional, Karmpaliotis, Dimitri, additional, Kassem, Hussien Heshmat, additional, Kearney, Kathleen, additional, Kerrigan, Jimmy, additional, Khatri, Jaikirshan, additional, Khelimskii, Dmitrii, additional, Kirtane, Ajay J., additional, Knaapen, Paul, additional, Kostantinis, Spyridon, additional, Koutouzis, Michalis, additional, Kovacic, Mihajlo, additional, Krestyaninov, Oleg, additional, Kumar, A.V. Ganesh, additional, Kumar N., Prathap, additional, Kunkel, Katherine J., additional, Lamelas, Pablo Manuel, additional, Lee, Seung-Whan, additional, Lefevre, Thierry, additional, Leibundgut, Gregor, additional, Lembo, Nicholas J., additional, Leon, Martin, additional, Lesser, John R., additional, Leung, Raymond, additional, Lim, Soo-Teik, additional, Lo, Sidney Tsz Ho, additional, Lombardi, William, additional, Luna, Michael, additional, Mahmud, Ehtisham, additional, Mahowald, Madeline K., additional, Maran, Anbukarasi, additional, Marmagkiolis, Konstantinos, additional, Martins Filho, Evandro, additional, Mashayekhi, Kambis, additional, McEntegart, Margaret B., additional, Megaly, Michael, additional, Meraj, Perwaiz, additional, Michalis, Lampros, additional, Milkas, Anastasios N., additional, Mogabgab, Owen, additional, Moses, Jeffrey, additional, Munawar, Muhammad, additional, Murad, Bilal, additional, Nap, Alexander, additional, Navarro, Andres, additional, Nicholson, William J., additional, Øksnes, Anja, additional, Olivecrona, Göran, additional, Omer, Mohamed A., additional, Oreglia, Jacopo Andrea, additional, Padilla, Lucio, additional, Patel, Mitul P., additional, Patel, Rajan A.G., additional, Patel, Taral, additional, Pershad, Ashish, additional, Pinto, Duane, additional, Poommipanit, Paul, additional, Postu, Marin, additional, Potluri, Srini, additional, Pyxaras, Stylianos, additional, Quadros, Alexandre Schaan de, additional, Ragosta, Michael, additional, Rao, Sunil V., additional, Rao, Vithala Surya Prakasa, additional, Rathore, Sudhir, additional, Reifart, Joerg, additional, Rempakos, Athanasios, additional, Rier, Jeremy, additional, Riley, Robert, additional, Rinfret, Stéphane, additional, Russo, Juan J., additional, Saghatelyan, Meruzhan, additional, Sandhu, Gurpreet S., additional, Sandoval, Yader, additional, Santiago, Ricardo, additional, Sapontis, James, additional, Shah, Alpesh, additional, Shlofmitz, Evan, additional, Shunk, Kendrick A., additional, Sianos, George, additional, Simsek, Bahadir, additional, Smith, Elliot J., additional, Spaedy, Anthony, additional, Spratt, James, additional, Strange, Julian W., additional, Strauss, Bradley, additional, Tajti, Péter, additional, Tamez, Hector, additional, Tammam, Khalid O., additional, Thompson, Craig A., additional, Toma, Aurel, additional, Toma, Catalin, additional, Tsiafoutis, Ioannis, additional, Tsuchikane, Etsuo, additional, Ungi, Imre, additional, Uretsky, Barry F., additional, Vlachojannis, Georgios J., additional, Vo, Minh Nhat, additional, Vu, Hoang Vu, additional, Walsh, Simon, additional, Weilenmann, Daniel, additional, Werner, Gerald, additional, Wójcik, Jarosław, additional, Wollmuth, Jason, additional, Wu, Eugene B., additional, Wyman, R. Michael, additional, Xenogiannis, Iosif, additional, Xu, Bo, additional, Yamane, Masahisa, additional, Ybarra, Luiz F., additional, and Yeh, Robert W., additional

Published
2023
Full Text
View/download PDF

6. List of contributors

Author

Abbott, J. Dawn, primary, Abi Rafeh, Nidal, additional, Abu Fadel, Mazen, additional, Agostoni, Pierfrancesco, additional, Akyuz, Sukru, additional, Alaswad, Khaldoon, additional, Alexopoulos, Dimitrios, additional, Angiolillo, Dominick J., additional, Aronow, Herbert D., additional, Avran, Alexandre, additional, Azzalini, Lorenzo, additional, Babunashvili, Avtandil M., additional, Bagai, Jayant, additional, Banerjee, Subhash, additional, Baran, Kenneth, additional, Basir, Mir Babar, additional, Boudou, Nicolas, additional, Boudoulas, Konstantinos Dean, additional, Bourantas, Christos V., additional, Božinović, Nenad Ž., additional, Bryniarski, Leszek, additional, Bufe, Alexander, additional, Burke, M. Nicholas, additional, Büttner, Heinz Joachim, additional, Cardoso, Pedro Pinto, additional, Carlino, Mauro, additional, Chambers, Jeff, additional, Charitakis, Konstantinos, additional, Chatzizisis, Yiannis S., additional, J. Chavez, Ivan, additional, Choi, James W., additional, Christiansen, Evald Høj, additional, Cohen, Mauricio G., additional, Costa, Francesco, additional, Damas de los Santos, Felix, additional, Dautov, Rustem, additional, De Martini, Tony, additional, Denktas, Ali E., additional, Dens, Joseph, additional, Dimitriadis, Zisis, additional, Doing, Anthony, additional, Egred, Mohaned, additional, Elbarouni, Basem, additional, El Guindy, Ahmed M., additional, El Sabbagh, Abdallah, additional, Fasseas, Panayotis, additional, Feldman, Dmitriy N., additional, Furkalo, Sergey, additional, Gagnor, Andrea, additional, Galassi, Alfredo R., additional, Garbo, Roberto, additional, Garcia, Santiago, additional, Gasparini, Gabriele L., additional, Gershlick, Anthony H., additional, Goessl, Mario, additional, Grancini, Luca, additional, Hakeem, Abdul, additional, Hall, Allison B., additional, Harb, Stefan, additional, Hatem, Raja, additional, Henriques, Jose P.S., additional, Jang, Yangsoo, additional, Jussila, Risto, additional, Kalnins, Artis, additional, Kalyanasundaram, Arun, additional, Kao, Paul Hsien-Li, additional, Karacsonyi, Judit, additional, Karagounis, Lampros, additional, Karanasos, Antonios, additional, Karmpaliotis, Dimitri, additional, Khalili, Houman, additional, Khatri, Jaikirshan J., additional, Khelimskii, Dmitrii, additional, Kim, Byeong-Keuk, additional, Kohl, Louis P., additional, Kolansky, Daniel M., additional, Koutouzis, Michalis, additional, Krestyaninov, Oleg, additional, Latif, Faisal, additional, Lee, Seung-Whan, additional, Lefevre, Thierry, additional, Lembo, Nicholas J., additional, Mahmud, Ehtisham, additional, Marmagkiolis, Konstantinos, additional, Mashayekhi, Kambis, additional, Mavromatis, Kreton, additional, Megaly, Michael, additional, Mogabgab, Owen, additional, Mooney, Michael R., additional, Moses, Jeffrey W., additional, Murad, Bilal, additional, Nap, Alexander, additional, Nicholson, William, additional, Nikas, Dimitrios N., additional, Nikolakopoulos, Ilias, additional, Olivecrona, Goran, additional, Omer, Mohamed A., additional, Oreglia, Jacopo Andrea, additional, Padilla, Lucio, additional, Paizis, Ioannis, additional, Panetta, Carmelo, additional, Patel, Mitul, additional, Pershad, Ashish, additional, Postu, Marin, additional, Potluri, Srini, additional, Poulose, Anil, additional, Pyxaras, Stylianos, additional, Rao, Sunil V., additional, Rathore, Sudhir, additional, Ravandi, Amir, additional, Reifart, Nicolaus, additional, Riley, Robert F., additional, Rinfret, Stephane, additional, Sandhu, Gurpreet S., additional, Sandoval, Yader, additional, Sanidas, Elias, additional, Santiago Trinidad, Ricardo, additional, Schussler, Jeffrey M., additional, Seto, Arnold, additional, Sharma, Alok, additional, Shaukat, Arslan, additional, Shishehbor, Mehdi H., additional, Shlofmitz, Evan, additional, Shlofmitz, Richard, additional, Sorajja, Paul, additional, Spaedy, Anthony, additional, Tajti, Peter, additional, Tamis-Holland, Jacqueline E., additional, Toma, Aurel, additional, Toutouzas, Konstantinos, additional, Traverse, Jay H., additional, Truong, Huu Tam, additional, Tsalamandris, Sotiris, additional, Tsiafoutis, Ioannis, additional, Ungi, Imre, additional, Vavouranakis, Emmanouil, additional, Vemmou, Evangelia, additional, Vo, Minh N., additional, Voudris, Vassilis, additional, Wang, Yale, additional, Wójcik, Jarosław, additional, Wollmuth, Jason, additional, Wu, Eugene B., additional, Xenogiannis, Iosif, additional, Yamane, Masahisa, additional, and Ybarra, Luiz Fernando, additional

Published
2021
Full Text
View/download PDF

7. Natural history and clinical burden of moderate aortic stenosis: a systematic review and explorative meta-analysis

Author

Morelli, M, Galasso, M, Esposito, G, Soriano, F, Nava, S, Da Pozzo, C, Bossi, I, Piccaluga, E, Bruschi, G, Maloberti, A, Oliva, F, Oreglia, J, Giannattasio, C, Montalto, C, Morelli, Martina, Galasso, Michele, Esposito, Giuseppe, Soriano, Francesco Stefano, Nava, Stefano, Da Pozzo, Caterina, Bossi, Irene, Piccaluga, Emanuela, Bruschi, Giuseppe, Maloberti, Alessandro, Oliva, Fabrizio, Oreglia, Jacopo Andrea, Giannattasio, Cristina, Montalto, Claudio, Morelli, M, Galasso, M, Esposito, G, Soriano, F, Nava, S, Da Pozzo, C, Bossi, I, Piccaluga, E, Bruschi, G, Maloberti, A, Oliva, F, Oreglia, J, Giannattasio, C, Montalto, C, Morelli, Martina, Galasso, Michele, Esposito, Giuseppe, Soriano, Francesco Stefano, Nava, Stefano, Da Pozzo, Caterina, Bossi, Irene, Piccaluga, Emanuela, Bruschi, Giuseppe, Maloberti, Alessandro, Oliva, Fabrizio, Oreglia, Jacopo Andrea, Giannattasio, Cristina, and Montalto, Claudio

Abstract

Aims: The mortality risk of patients with moderate aortic stenosis is not well known, but recent studies suggested that it might negatively affect prognosis. We aimed to assess the natural history and clinical burden of moderate aortic stenosis and to investigate the interaction of patients' baseline characteristics with prognosis. Methods: Systematic research was conducted on PubMed. The inclusion criteria were inclusion of patients with moderate aortic stenosis; and report of the survival at 1-year follow-up (minimum). Incidence ratios related to all-cause mortality in patients and controls of each study were estimated and then pooled using a fixed effects model. All patients with mild aortic stenosis or without aortic stenosis were considered controls. Meta-regression analysis was performed to assess the impact of left ventricular ejection fraction and age on the prognosis of patients with moderate aortic stenosis. Results: Fifteen studies and 11 596 patients with moderate aortic stenosis were included. All-cause mortality was significantly higher among patients with moderate aortic stenosis than in controls in all timeframes analysed (all P < 0.0001). Left ventricular ejection fraction and sex did not significantly impact on the prognosis of patients with moderate aortic stenosis (P = 0.4584 and P = 0.5792), while increasing age showed a significant interaction with mortality (estimate = 0.0067; 95% confidence interval: 0.0007-0.0127; P = 0.0323). Conclusion: Moderate aortic stenosis is associated with reduced survival. Further studies are necessary to confirm the prognostic impact of this valvulopathy and the possible benefit of aortic valve replacement.

Published
2023

8. Impact of SGLT2-inhibitors on contrast-induced acute kidney injury in Diabetic patients with Acute Myocardial Infarction: Insight from SGLT2-I AMI PROTECT Registry

Author

Paolisso, Pasquale, primary, Bergamaschi, Luca, additional, Cesaro, Arturo, additional, Gallinoro, Emanuele, additional, Gragnano, Felice, additional, Sardu, Celestino, additional, Mileva, Niya, additional, Foà, Alberto, additional, Armillotta, Matteo, additional, Sansonetti, Angelo, additional, Amicone, Sara, additional, Impellizzeri, Andrea, additional, Belmonte, Marta, additional, Esposito, Giuseppe, additional, Morici, Nuccia, additional, Oreglia, Jacopo Andrea, additional, Casella, Gianni, additional, Mauro, Ciro, additional, Vassilev, Dobrin, additional, Galiè, Nazzareno, additional, Santulli, Gaetano, additional, Calabrò, Paolo, additional, Barbato, Emanuele, additional, Marfella, Raffaele, additional, and Pizzi, Carmine, additional

Published
2023
Full Text
View/download PDF

9. 456 NATURAL HISTORY AND CLINICAL BURDEN OF MODERATE AORTIC STENOSIS: A SYSTEMATIC REVIEW AND META-ANALYSIS

Author

Morelli, Martina, primary, Galasso, Michele, additional, Soriano, Francesco Stefano, additional, Nava, Stefano, additional, Da Pozzo, Caterina, additional, Esposito, Giuseppe, additional, Piccaluga, Emanuela, additional, Bossi, Irene, additional, Montalto, Claudio, additional, Oreglia, Jacopo Andrea, additional, and Giannattasio, Cristina, additional

Published
2022
Full Text
View/download PDF

10. 528 OUTCOMES IN DIABETIC PATIENTS WITH ACUTE MYOCARDIAL INFARCTION TREATED WITH SGLT2-I: THE SGLT2-I AMI PROTECT REGISTRY

Author

Paolisso, Pasquale, primary, Bergamaschi, Luca, additional, Gragnano, Felice, additional, Gallinoro, Emanuele, additional, Cesaro, Arturo, additional, Sardu, Celestino, additional, Mileva, Niya, additional, Foà, Alberto, additional, Armillotta, Matteo, additional, Sansonetti, Angelo, additional, Amicone, Sara, additional, Impellizzeri, Andrea, additional, Esposito, Giuseppe, additional, Morici, Nuccia, additional, Oreglia, Jacopo Andrea, additional, Casella, Gianni, additional, Mauro, Ciro, additional, Vassilev, Dobrin, additional, Galiè, Nazzareno, additional, Marfella, Raffaele, additional, Santulli, Gaetano, additional, Calabrò, Paolo, additional, Pizzi, Carmine, additional, and Barbato, Emanuele, additional

Published
2022
Full Text
View/download PDF

12. In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: Insights from the SGLT2-I AMI PROTECT study

Author

Cesaro, Arturo, primary, Gragnano, Felice, additional, Paolisso, Pasquale, additional, Bergamaschi, Luca, additional, Gallinoro, Emanuele, additional, Sardu, Celestino, additional, Mileva, Niya, additional, Foà, Alberto, additional, Armillotta, Matteo, additional, Sansonetti, Angelo, additional, Amicone, Sara, additional, Impellizzeri, Andrea, additional, Esposito, Giuseppe, additional, Morici, Nuccia, additional, Oreglia, Jacopo Andrea, additional, Casella, Gianni, additional, Mauro, Ciro, additional, Vassilev, Dobrin, additional, Galie, Nazzareno, additional, Santulli, Gaetano, additional, Pizzi, Carmine, additional, Barbato, Emanuele, additional, Calabrò, Paolo, additional, and Marfella, Raffaele, additional

Published
2022
Full Text
View/download PDF

15. Large-bore arterial access closure after transcatheter aortic valve replacement: a systematic review and network meta-analysis

Author

Montalto, Claudio, primary, Munafò, Andrea Raffaele, additional, Arzuffi, Luca, additional, Soriano, Francesco, additional, Mangieri, Antonio, additional, Nava, Stefano, additional, De Maria, Giovanni Luigi, additional, Burzotta, Francesco, additional, D’Ascenzo, Fabrizio, additional, Colombo, Antonio, additional, Latib, Azeem, additional, Oreglia, Jacopo Andrea, additional, Banning, Adrian P, additional, Porto, Italo, additional, and Crimi, Gabriele, additional

Published
2022
Full Text
View/download PDF

16. Large-bore arterial access closure after transcatheter aortic valve replacement: a systematic review and network meta-analysis

Author

Montalto, Claudio, Munafò, Andrea Raffaele, Arzuffi, Luca, Soriano, Francesco, Mangieri, Antonio, Nava, Stefano, De Maria, Giovanni Luigi, Burzotta, Francesco, D'Ascenzo, Fabrizio, Colombo, Antonio, Latib, Azeem, Oreglia, Jacopo Andrea, Banning, Adrian P, Porto, Italo, Crimi, Gabriele, De Maria, Giovanni Luigi (ORCID:0000-0003-3572-1855), Burzotta, Francesco (ORCID:0000-0002-6569-9401), Porto, Italo (ORCID:0000-0002-9854-5046), Montalto, Claudio, Munafò, Andrea Raffaele, Arzuffi, Luca, Soriano, Francesco, Mangieri, Antonio, Nava, Stefano, De Maria, Giovanni Luigi, Burzotta, Francesco, D'Ascenzo, Fabrizio, Colombo, Antonio, Latib, Azeem, Oreglia, Jacopo Andrea, Banning, Adrian P, Porto, Italo, Crimi, Gabriele, De Maria, Giovanni Luigi (ORCID:0000-0003-3572-1855), Burzotta, Francesco (ORCID:0000-0002-6569-9401), and Porto, Italo (ORCID:0000-0002-9854-5046)

Abstract

As the indications to transcatheter aortic valve replacement (TAVR) expand to patients at increasingly lower risk, procedure-related vascular and bleeding complications events must be minimized. We aimed to evaluate the impact of different large-bore arterial access closure devices on clinical outcomes after TAVR.

Published
2022

18. Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT Registry

Author

Pasquale Paolisso, Luca Bergamaschi, Felice Gragnano, Emanuele Gallinoro, Arturo Cesaro, Celestino Sardu, Niya Mileva, Alberto Foà, Matteo Armillotta, Angelo Sansonetti, Sara Amicone, Andrea Impellizzeri, Giuseppe Esposito, Nuccia Morici, Oreglia Jacopo Andrea, Gianni Casella, Ciro Mauro, Dobrin Vassilev, Nazzareno Galie, Gaetano Santulli, Raffaele Marfella, Paolo Calabrò, Carmine Pizzi, Emanuele Barbato, Paolisso, Pasquale, Bergamaschi, Luca, Gragnano, Felice, Gallinoro, Emanuele, Cesaro, Arturo, Sardu, Celestino, Mileva, Niya, Foà, Alberto, Armillotta, Matteo, Sansonetti, Angelo, Amicone, Sara, Impellizzeri, Andrea, Esposito, Giuseppe, Nuccia, Morici, Andrea, Oreglia Jacopo, Casella, Gianni, Mauro, Ciro, Vassilev, Dobrin, Galie, Nazzareno, Santulli, Gaetano, Marfella, Raffaele, Calabro', Paolo, Pizzi, Carmine, Barbato, Emanuele, Paolisso P., Bergamaschi L., Gragnano F., Gallinoro E., Cesaro A., Sardu C., Mileva N., Foa A., Armillotta M., Sansonetti A., Amicone S., Impellizzeri A., Esposito G., Nuccia M., Andrea O.J., Casella G., Mauro C., Vassilev D., Galie N., Santulli G., Marfella R., Calabro P., Pizzi C., and Barbato E.

Subjects
Pharmacology, Acute myocardial infarction, SGLT2-I, Arrhythmia, HF hospitalization, Outcome
Abstract

Aims: To investigate in-hospital and long-term prognosis in T2DM patients presenting with acute myocardial infarction (AMI) treated with SGLT2-I versus other oral anti-diabetic agents (non-SGLT2-I users). Methods: In this multicenter international registry all consecutive diabetic AMI patients undergoing percutaneous coronary intervention between 2018 and 2021 were enrolled and, based on the admission anti-diabetic therapy, divided into SGLT-I users versus non-SGLT2-I users. The primary endpoint was defined as a composite of cardiovascular death, recurrent AMI, and hospitalization for HF (MACE). Secondary outcomes included i) in-hospital cardiovascular death, recurrent AMI, occurrence of arrhythmias, and contrast-induced acute kidney injury (CI-AKI); ii) long-term cardiovascular mortality, recurrent AMI, heart failure (HF) hospitalization. Results: The study population consisted of 646 AMI patients (with or without ST-segment elevation): 111 SGLT2-I users and 535 non-SGLT-I users. The use of SGLT2-I was associated with a significantly lower in-hospital cardiovascular death, arrhythmic burden, and occurrence of CI-AKI (all p < 0.05). During a median follow-up of 24 ± 13 months, the primary composite endpoint, as well as cardiovascular mortality and HF hospitalization were lower for SGLT2-I users compared to non-SGLT2-I patients (p < 0.04 for all). After adjusting for confounding factors, the use of SGLT2-I was identified as independent predictor of reduced MACE occurrence (HR=0.57; 95%CI:0.33–0.99; p = 0.039) and HF hospitalization (HR=0.46; 95%CI:0.21–0.98; p = 0.041). Conclusions: In T2DM AMI patients, the use of SGLT2-I was associated with a lower risk of adverse cardiovascular outcomes during index hospitalization and long-term follow-up. Our findings provide new insights into the cardioprotective effects of SGLT2-I in the setting of AMI. Registration: Data are part of the observational international registry: SGLT2-I AMI PROTECT. ClinicalTrials.gov Identifier: NCT05261867.

Published
2023
Full Text
View/download PDF

20. Correction: SGLT2-inhibitors in diabetic patients with severe aortic stenosis and cardiac damage undergoing transcatheter aortic valve implantation (TAVI)

Author

Paolisso, Pasquale, Belmonte, Marta, Gallinoro, Emanuele, Scarsini, Roberto, Bergamaschi, Luca, Portolan, Leonardo, Armillotta, Matteo, Esposito, Giuseppe, Moscarella, Elisabetta, Benfari, Giovanni, Montalto, Claudio, Shumkova, Monika, de Oliveira, Elayne Kelen, Angeli, Francesco, Orzalkiewicz, Mateusz, Fabroni, Margherita, Baydaroglu, Nurcan, Munafò, Andrea Raffaele, D’Atri, Daniele Oreste, Casenghi, Matteo, Scisciola, Lucia, Barbieri, Michelangela, Marfella, Raffaele, Gragnano, Felice, Conte, Edoardo, Pellegrini, Dario, Ielasi, Alfonso, Andreini, Daniele, Penicka, Martin, Oreglia, Jacopo Andrea, Calabrò, Paolo, Bartorelli, Antonio, Pizzi, Carmine, Palmerini, Tullio, Vanderheyden, Marc, Saia, Francesco, Ribichini, Flavio, and Barbato, Emanuele

Published
2025
Full Text
View/download PDF

23. [Updated SICI-GISE position paper on institutional and operator requirements for transcatheter aortic valve implantation]

Author

Tarantini, Giuseppe, Esposito, Giovanni, Musumeci, Giuseppe, Fraccaro, Chiara, Franzone, Anna, Castiglioni, Battistina, La Manna, Alessio, Limbruno, Ugo, Marchese, Alfredo, Mauro, Ciro, Rigattieri, Stefano, Tarantino, Fabio, Gandolfo, Caterina, Santoro, Gennaro, Violini, Roberto, Airoldi, Flavio, Albiero, Remo, Balbi, Manrico, Baralis, Giorgio, Bartorelli, Antonio Luca, Bedogni, Francesco, Benassi, Alberto, Berni, Andrea, Bonzani, Giulio, Bortone, Alessandro Santo, Braito, Giuseppe, Briguori, Carlo, Brscic, Elvis, Calabrò, Paolo, Calchera, Ivan, Cappelli Bigazzi, Maurizio, Caprioglio, Francesco, Castriota, Fausto, Cernetti, Carlo, Cicala, Cinzia, Cioffi, Paolo, Colombo, Antonio, Colombo, Virgilio, Contegiacomo, Gaetano, Cremonesi, Alberto, D'Amico, Maurizio, De Benedictis, Mauro, De Leo, Alessandro, Di Biasi, Maurizio, Di Girolamo, Domenico, Di Lorenzo, Emilio, Di Mario, Carlo, Dominici, Marcello, Ettori, Federica, Ferrario, Maurizio, Fioranelli, Massimo, Fischetti, Dionigi, Gabrielli, Gabriele, Giordano, Arturo, Giudice, Pietro, Greco, Cesare, Indolfi, Ciro, Leonzi, Ornella, Lettieri, Corrado, Loi, Bruno, Maddestra, Nicola, Marchionni, Niccolò, Marrozzini, Cinzia, Medda, Massimo, Missiroli, Bindo, My, Luigi, Oreglia, Jacopo Andrea, Palmieri, Cataldo, Pantaleo, Paolo, Paparoni, Saro Roberto, Parodi, Guido, Petronio, Anna Sonia, Piatti, Luigi, Piccaluga, Emanuela, Pierli, Carlo, Perkan, Andrea, Pitì, Antonino, Poli, Arnaldo, Ramondo, Angelo Bruno, Reale, Maurizio Alessandro, Reimers, Bernhard, Ribichini, Flavio Luciano, Rosso, Roberta, Saccà, Salvatore, Sacra, Cosimo, Santarelli, Andrea, Sardella, Gennaro, Satullo, Gaetano, Scalise, Filippo, Siviglia, Massimo, Spedicato, Leonardo, Stabile, Amerigo, Tamburino, Corrado, Tesorio, Tullio Nicola Maria, Tolaro, Salvatore, Tomai, Fabrizio, Trani, Carlo, Valenti, Renato, Valsecchi, Orazio, Valva, Giuseppe, Varbella, Ferdinando, Vigna, Carlo, Vignali, Luigi, Berti, Sergio, Tarantini, Giuseppe, Esposito, Giovanni, Musumeci, Giuseppe, Fraccaro, Chiara, Franzone, Anna, Castiglioni, Battistina, La Manna, Alessio, Limbruno, Ugo, Marchese, Alfredo, Mauro, Ciro, Rigattieri, Stefano, Tarantino, Fabio, Gandolfo, Caterina, Santoro, Gennaro, Violini, Roberto, Airoldi, Flavio, Albiero, Remo, Balbi, Manrico, Baralis, Giorgio, Bartorelli, Antonio Luca, Bedogni, Francesco, Benassi, Alberto, Berni, Andrea, Bonzani, Giulio, Bortone, Alessandro Santo, Braito, Giuseppe, Briguori, Carlo, Brscic, Elvi, Calabrò, Paolo, Calchera, Ivan, Cappelli Bigazzi, Maurizio, Caprioglio, Francesco, Castriota, Fausto, Cernetti, Carlo, Cicala, Cinzia, Cioffi, Paolo, Colombo, Antonio, Colombo, Virgilio, Contegiacomo, Gaetano, Cremonesi, Alberto, D'Amico, Maurizio, De Benedictis, Mauro, De Leo, Alessandro, Di Biasi, Maurizio, Di Girolamo, Domenico, Di Lorenzo, Emilio, Di Mario, Carlo, Dominici, Marcello, Ettori, Federica, Ferrario, Maurizio, Fioranelli, Massimo, Fischetti, Dionigi, Gabrielli, Gabriele, Giordano, Arturo, Giudice, Pietro, Greco, Cesare, Indolfi, Ciro, Leonzi, Ornella, Lettieri, Corrado, Loi, Bruno, Maddestra, Nicola, Marchionni, Niccolò, Marrozzini, Cinzia, Medda, Massimo, Missiroli, Bindo, My, Luigi, Oreglia, Jacopo Andrea, Palmieri, Cataldo, Pantaleo, Paolo, Paparoni, Saro Roberto, Parodi, Guido, Petronio, Anna Sonia, Piatti, Luigi, Piccaluga, Emanuela, Pierli, Carlo, Perkan, Andrea, Pitì, Antonino, Poli, Arnaldo, Ramondo, Angelo Bruno, Reale, Maurizio Alessandro, Reimers, Bernhard, Ribichini, Flavio Luciano, Rosso, Roberta, Saccà, Salvatore, Sacra, Cosimo, Santarelli, Andrea, Sardella, Gennaro, Satullo, Gaetano, Scalise, Filippo, Siviglia, Massimo, Spedicato, Leonardo, Stabile, Amerigo, Tamburino, Corrado, Tesorio, Tullio Nicola Maria, Tolaro, Salvatore, Tomai, Fabrizio, Trani, Carlo, Valenti, Renato, Valsecchi, Orazio, Valva, Giuseppe, Varbella, Ferdinando, Vigna, Carlo, Vignali, Luigi, and Berti, Sergio

Subjects
Transcatheter aortic valve implantation, Transcatheter aortic valve implantation, TAVI, severe aortic stenosis, Operators, Biomedical Technology, Requirements, Aortic Valve Stenosis, Institutions, Severity of Illness Index, Transcatheter Aortic Valve Replacement, TAVI, Italy, Settore MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARE, Training, Humans, Program Development, severe aortic stenosis
Abstract

Transcatheter aortic valve implantation (TAVI) has revolutionized the management of patients with symptomatic severe aortic stenosis and has become the standard of care for inoperable patients and the preferred therapy for those at increased surgical risk with peculiar clinical and anatomic features. Technology advances, growing experience and accumulating data prompted the update of the 2011 Italian Society of Interventional Cardiology (SICI-GISE) position paper on institutional and operator requirements to perform TAVI. The main objective of this document is to provide a guidance to assess the potential of institutions and operators to initiate and maintain an efficient TAVI program.

Published
2018

24. Documento di consenso ANMCO/AIAC/SICI-GISE/SIC/SICCH: Chiusura percutanea dell'auricola sinistra in pazienti con fibrillazione atriale non valvolare: Indicazioni, selezione del paziente, competenze e organizzazione e formazione degli operatori

Author

Casu, Gavino, Gulizia, Michele Massimo, Molon, Giulio, Mazzone, Patrizio, Audo, Andrea, Casolo, Giancarlo, Di Lorenzo, Emilio, Portoghese, Michele, Pristipino, Christian, Ricci, Renato Pietro, Themistoclakis, Sakis, Padeletti, Luigi, Tondo, Claudio, Berti, Sergio, Oreglia, Jacopo Andrea, Gerosa, Gino, Zanobini, Marco, Ussia, Gian Paolo, Musumeci, Giuseppe, Romeo, Francesco, DI BARTOLOMEO, ROBERTO, Casu, Gavino, Gulizia, Michele Massimo, Molon, Giulio, Mazzone, Patrizio, Audo, Andrea, Casolo, Giancarlo, Di Lorenzo, Emilio, Portoghese, Michele, Pristipino, Christian, Ricci, Renato Pietro, Themistoclakis, Saki, Padeletti, Luigi, Tondo, Claudio, Berti, Sergio, Oreglia, Jacopo Andrea, Gerosa, Gino, Zanobini, Marco, Ussia, Gian Paolo, Musumeci, Giuseppe, Romeo, Francesco, and Di Bartolomeo, Roberto

Subjects
Left atrial appendage occlusion, Cardiology and Cardiovascular Medicine, Atrial fibrillation
Abstract

Atrial fibrillation (AF) is the most common arrhythmia and its prevalence is increasing due to the progressive aging of the population. About 20% of strokes are attributable to AF and AF patients are at 5-fold increased risk of stroke. The mainstay of treatment of AF is the prevention of thromboembolic complications with oral anticoagulation therapy. Drug treatment for many years has been based on the use of Vitamin K antagonists, but recently newer and safer molecules have been introduced (dabigatran etexilate, rivaroxaban, apixaban and edoxaban). Despite these advances, many patients still do not receive adequate anticoagulation therapy because of contraindications (relative and absolute) to this treatment. Over the last decade, percutaneous closure of left atrial appendage, main site of thrombus formation during AF, proved effective in reducing thromboembolic complications, thus offering a valid medical treatment especially in patients at increased bleeding risk. The aim of this consensus document is to review the main aspects of left atrial appendage occlusion (selection and multidisciplinary assessment of patients, currently available methods and devices, requirements for centers and operators, associated therapies and follow-up modalities) having as a ground the significant evolution of techniques and the available relevant clinical data.

Published
2016

26. ANMCO/AIAC/SICI-GISE/SIC/SICCH Consensus Document: percutaneous occlusion of the left atrial appendage in non-valvular atrial fibrillation patients: indications, patient selection, staff skills, organisation, and training

Author

Casu, Gavino, primary, Gulizia, Michele Massimo, additional, Molon, Giulio, additional, Mazzone, Patrizio, additional, Audo, Andrea, additional, Casolo, Giancarlo, additional, Di Lorenzo, Emilio, additional, Portoghese, Michele, additional, Pristipino, Christian, additional, Ricci, Renato Pietro, additional, Themistoclakis, Sakis, additional, Padeletti, Luigi, additional, Tondo, Claudio, additional, Berti, Sergio, additional, Oreglia, Jacopo Andrea, additional, Gerosa, Gino, additional, Zanobini, Marco, additional, Ussia, Gian Paolo, additional, Musumeci, Giuseppe, additional, Romeo, Francesco, additional, and Di Bartolomeo, Roberto, additional

Published
2017
Full Text
View/download PDF

27. TCT-622 Efficay and safety of left atrial appendage closure with three different devices: peri-procedural and mid-term outcomes from a in a “real world” registry

Author

Oreglia, Jacopo Andrea, primary, Danna, Paolo, additional, Pernigotti, Alberto, additional, Vizzi, Vincenzo, additional, Di Biasi, Maurizio, additional, Colombo, Alessandro, additional, Barosi, Alberto, additional, Colombo, Simone, additional, Telli, Gaia, additional, and Viecca, Maurizio, additional

Published
2016
Full Text
View/download PDF

29. In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: Insights from the SGLT2-I AMI PROTECT study

Author

Arturo Cesaro, Felice Gragnano, Pasquale Paolisso, Luca Bergamaschi, Emanuele Gallinoro, Celestino Sardu, Niya Mileva, Alberto Foà, Matteo Armillotta, Angelo Sansonetti, Sara Amicone, Andrea Impellizzeri, Giuseppe Esposito, Nuccia Morici, Jacopo Andrea Oreglia, Gianni Casella, Ciro Mauro, Dobrin Vassilev, Nazzareno Galie, Gaetano Santulli, Carmine Pizzi, Emanuele Barbato, Paolo Calabrò, Raffaele Marfella, Cesaro, Arturo, Gragnano, Felice, Paolisso, Pasquale, Bergamaschi, Luca, Gallinoro, Emanuele, Sardu, Celestino, Mileva, Niya, Foà, Alberto, Armillotta, Matteo, Sansonetti, Angelo, Amicone, Sara, Impellizzeri, Andrea, Esposito, Giuseppe, Morici, Nuccia, Oreglia, Jacopo Andrea, Casella, Gianni, Mauro, Ciro, Vassilev, Dobrin, Galie, Nazzareno, Santulli, Gaetano, Pizzi, Carmine, Barbato, Emanuele, Calabrò, Paolo, Marfella, Raffaele, Calabro, Paolo, and Foa, Alberto

Subjects
sodium-glucose cotransporter 2 inhibitors (SGLT2-i), acute myocardial infarction, atrial fibrillation, hyperglycemia, ventricular tachycardia, Cardiology and Cardiovascular Medicine, ventricular arrhythmia
Abstract

BackgroundSodium-glucose co-transporter 2 inhibitors (SGLT2-i) have shown significant cardiovascular benefits in patients with and without type 2 diabetes mellitus (T2DM). They have also gained interest for their potential anti-arrhythmic role and their ability to reduce the occurrence of atrial fibrillation (AF) and ventricular arrhythmias (VAs) in T2DM and heart failure patients.ObjectivesTo investigate in-hospital new-onset cardiac arrhythmias in a cohort of T2DM patients presenting with acute myocardial infarction (AMI) treated with SGLT2-i vs. other oral anti-diabetic agents (non-SGLT2-i users).MethodsPatients from the SGLT2-I AMI PROTECT registry (NCT05261867) were stratified according to the use of SGLT2-i before admission for AMI, divided into SGLT2-i users vs. non-SGLT2-i users. In-hospital outcomes included the occurrence of in-hospital new-onset cardiac arrhythmias (NOCAs), defined as a composite of new-onset AF and sustained new-onset ventricular tachycardia (VT) and/or ventricular fibrillation (VF) during hospitalization.ResultsThe study population comprised 646 AMI patients categorized into SGLT2-i users (111 patients) and non-SGLT2-i users (535 patients). SGLT2-i users had a lower rate of NOCAs compared with non-SGLT2-i users (6.3 vs. 15.7%, p = 0.010). Moreover, SGLT2-i was associated with a lower rate of AF and VT/VF considered individually (p = 0.032). In the multivariate logistic regression model, after adjusting for all confounding factors, the use of SGLT2-i was identified as an independent predictor of the lower occurrence of NOCAs (OR = 0.35; 95%CI 0.14–0.86; p = 0.022). At multinomial logistic regression, after adjusting for potential confounders, SGLT2-i therapy remained an independent predictor of VT/VF occurrence (OR = 0.20; 95%CI 0.04–0.97; p = 0.046) but not of AF occurrence.ConclusionsIn T2DM patients, the use of SGLT2-i was associated with a lower risk of new-onset arrhythmic events during hospitalization for AMI. In particular, the primary effect was expressed in the reduction of VAs. These findings emphasize the cardioprotective effects of SGLT2-i in the setting of AMI beyond glycemic control.Trial registrationData are part of the observational international registry: SGLT2-I AMI PROTECT. ClinicalTrials.gov, identifier: NCT05261867.

Published
2022
Full Text
View/download PDF

30. Update of the position document of the Italian Society of Interventional Cardiology (SICI-GISE) on the minimum requirements for hospitals and operators performing procedures of a transcatheter implantation of aortic valve prostheses

Author

Tarantini, G., Esposito, G., Musumeci, G., Fraccaro, C., Franzone, A., Castiglioni, B., La Manna, A., Limbruno, U., Marchese, A., Mauro, C., Rigattieri, S., Tarantino, F., Gandolfo, C., Santoro, G., Violini, R., Airoldi, F., Albiero, R., Balbi, M., Baralis, G., Bartorelli, A.L., Bedogni, F., Benassi, A., Berni, A., Bonzani, G., Bortone, A.S., Braito, G., Briguori, C., Brscic, E., Calabrò, P., Calchera, I., Bigazzi, M.C., Caprioglio, F., Castriota, F., Cernetti, C., Cicala, C., Cioffi, P., Colombo, A., Colombo, V., Contegiacomo, G., Cremonesi, A., D'Amico, M., De Benedictis, M., De Leo, A., Di Biasi, M., Di Girolamo, D., Di Lorenzo, E., Di Mario, C., Dominici, M., Ettori, F., Ferrario, M., Fioranelli, M., Fischetti, D., Gabrielli, G., Giordano, A., Giudice, P., Greco, C., Indolfi, C., Leonzi, O., Lettieri, C., Loi, B., Maddestra, N., Marchionni, N., Marrozzini, C., Medda, M., Missiroli, B., Luigi, M., Oreglia, J.A., Palmieri, C., Pantaleo, P., Paparoni, S.R., Parodi, G., Petronio, A.S., Piatti, L., Piccaluga, E., Pierli, C., Perkan, A., Pitì, A., Poli, A., Ramondo, A.B., Reale, M.A., Reimers, B., Ribichini, F.L., Rosso, R., Saccà, S., Sacra, C., Santarelli, A., Sardella, G., Satullo, G., Scalise, F., Siviglia, M., Spedicato, L., Stabile, A., Tamburino, C., Tesorio, T.N.M., Tolaro, S., Tomai, F., Trani, C., Valenti, R., Valsecchi, O., Valva, G., Varbella, F., Vigna, C., Vignali, L., Berti, S., Tarantini, Giuseppe, Esposito, Giovanni, Musumeci, Giuseppe, Fraccaro, Chiara, Franzone, Anna, Castiglioni, Battistina, La Manna, Alessio, Limbruno, Ugo, Marchese, Alfredo, Mauro, Ciro, Rigattieri, Stefano, Tarantino, Fabio, Gandolfo, Caterina, Santoro, Gennaro, Violini, Roberto, Airoldi, Flavio, Albiero, Remo, Balbi, Manrico, Baralis, Giorgio, Bartorelli, Antonio Luca, Bedogni, Francesco, Benassi, Alberto, Berni, Andrea, Bonzani, Giulio, Bortone, Alessandro Santo, Braito, Giuseppe, Briguori, Carlo, Brscic, Elvi, Calabrò, Paolo, Calchera, Ivan, Cappelli Bigazzi, Maurizio, Caprioglio, Francesco, Castriota, Fausto, Cernetti, Carlo, Cicala, Cinzia, Cioffi, Paolo, Colombo, Antonio, Colombo, Virgilio, Contegiacomo, Gaetano, Cremonesi, Alberto, D'Amico, Maurizio, De Benedictis, Mauro, De Leo, Alessandro, Di Biasi, Maurizio, Di Girolamo, Domenico, Di Lorenzo, Emilio, Di Mario, Carlo, Dominici, Marcello, Ettori, Federica, Ferrario, Maurizio, Fioranelli, Massimo, Fischetti, Dionigi, Gabrielli, Gabriele, Giordano, Arturo, Giudice, Pietro, Greco, Cesare, Indolfi, Ciro, Leonzi, Ornella, Lettieri, Corrado, Loi, Bruno, Maddestra, Nicola, Marchionni, Niccolò, Marrozzini, Cinzia, Medda, Massimo, Missiroli, Bindo, Luigi, My, Oreglia, Jacopo Andrea, Palmieri, Cataldo, Pantaleo, Paolo, Paparoni, Saro Roberto, Parodi, Guido, Petronio, Anna Sonia, Piatti, Luigi, Piccaluga, Emanuela, Pierli, Carlo, Perkan, Andrea, Pitì, Antonino, Poli, Arnaldo, Ramondo, Angelo Bruno, Reale, Maurizio Alessandro, Reimers, Bernhard, Ribichini, Flavio Luciano, Rosso, Roberta, Saccà, Salvatore, Sacra, Cosimo, Santarelli, Andrea, Sardella, Gennaro, Satullo, Gaetano, Scalise, Filippo, Siviglia, Massimo, Spedicato, Leonardo, Stabile, Amerigo, Tamburino, Corrado, Tesorio, Tullio Nicola Maria, Tolaro, Salvatore, Tomai, Fabrizio, Trani, Carlo, Valenti, Renato, Valsecchi, Orazio, Valva, Giuseppe, Varbella, Ferdinando, Vigna, Carlo, Vignali, Luigi, and Berti, Sergio

Subjects
Transcatheter aortic valve implantation, Institutions, Operators, Requirements, Training, Cardiology and Cardiovascular Medicine, Requirement, Institution, Operator, Settore MED/11 - Malattie dell'Apparato Cardiovascolare
Abstract

Transcatheter aortic valve implantation (TAVI) has revolutionized the management of patients with symptomatic severe aortic stenosis and has become the standard of care for inoperable patients and the preferred therapy for those at increased surgical risk with peculiar clinical and anatomic features. Technology advances, growing experience and accumulating data prompted the update of the 2011 Italian Society of Interventional Cardiology (SICI-GISE) position paper on institutional and operator requirements to perform TAVI. The main objective of this document is to provide a guidance to assess the potential of institutions and operators to initiate and maintain an efficient TAVI program. Transcatheter aortic valve implantation (TAVI) has revolutionized the management of patients with symptomatic severe aortic stenosis and has become the standard of care for inoperable patients and the preferred therapy for those at increased surgical risk with peculiar clinical and anatomic features. Technology advances, growing experience and accumulating data prompted the update of the 2011 Italian Society of Interventional Cardiology (SICI-GISE) position paper on institutional and operator requirements to perform TAVI. The main objective of this document is to provide a guidance to assess the potential of institutions and operators to initiate and maintain an efficient TAVI program.

Published
2018

31. ANMCO/AIAC/SICI-GISE/SIC/SICCH Consensus Document: Percutaneous occlusion of the left atrial appendage in non-valvular atrial fibrillation patients: Indications, patient selection, staff skills, organisation, and training

Author

Michele Massimo Gulizia, Giuseppe Musumeci, Giancarlo Casolo, Sakis Themistoclakis, Claudio Tondo, Marco Zanobini, Christian Pristipino, Giulio Molon, Jacopo Oreglia, Roberto Di Bartolomeo, Gino Gerosa, Gian Paolo Ussia, Andrea Audo, Renato Pietro Ricci, Patrizio Mazzone, Luigi Padeletti, Gavino Casu, Michele Portoghese, Sergio Berti, Emilio Di Lorenzo, Francesco Romeo, Casu, Gavino, Gulizia, Michele Massimo, Molon, Giulio, Mazzone, Patrizio, Audo, Andrea, Casolo, Giancarlo, Di Lorenzo, Emilio, Portoghese, Michele, Pristipino, Christian, Ricci, Renato Pietro, Themistoclakis, Saki, Padeletti, Luigi, Tondo, Claudio, Berti, Sergio, Oreglia, Jacopo Andrea, Gerosa, Gino, Zanobini, Marco, Ussia, Gian Paolo, Musumeci, Giuseppe, Romeo, Francesco, and Di Bartolomeo, Roberto

Subjects
medicine.medical_specialty, medicine.medical_treatment, Population, 030204 cardiovascular system & hematology, Left atrial appendage occlusion, Dabigatran, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Edoxaban, Internal medicine, medicine, 030212 general & internal medicine, Intensive care medicine, education, Stroke, Rivaroxaban, education.field_of_study, business.industry, Atrial fibrillation, Articles, medicine.disease, 3. Good health, chemistry, Cardiology, Apixaban, business, Cardiology and Cardiovascular Medicine, medicine.drug
Abstract

Atrial fibrillation (AF) is the most common arrhythmia and its prevalence is increasing due to the progressive aging of the population. About 20% of strokes are attributable to AF and AF patients are at five-fold increased risk of stroke. The mainstay of treatment of AF is the prevention of thromboembolic complications with oral anticoagulation therapy. Drug treatment for many years has been based on the use of vitamin K antagonists, but recently newer and safer molecules have been introduced (dabigatran etexilate, rivaroxaban, apixaban, and edoxaban). Despite these advances, many patients still do not receive adequate anticoagulation therapy because of contraindications (relative and absolute) to this treatment. Over the last decade, percutaneous closure of left atrial appendage, main site of thrombus formation during AF, proved effective in reducing thromboembolic complications, thus offering a valid medical treatment especially in patients at increased bleeding risk. The aim of this consensus document is to review the main aspects of left atrial appendage occlusion (selection and multidisciplinary assessment of patients, currently available methods and devices, requirements for centres and operators, associated therapies and follow-up modalities) having as a ground the significant evolution of techniques and the available relevant clinical data.

Published
2017

32. No-Reflow Complicating Chronic Total Occlusion Coronary Revascularization.

Author

Dall'Ara G, Testa L, Tumscitz C, Mattesini A, Gasparini GL, Grotti S, Bollati M, Tarantino F, Di Mario C, and Oreglia JA

Subjects
Coronary Angiography methods, Coronary Vessels diagnostic imaging, Coronary Vessels physiopathology, Coronary Vessels surgery, Diagnosis, Differential, Female, Humans, Male, Middle Aged, Outcome and Process Assessment, Health Care, Ultrasonography, Interventional methods, Vasodilator Agents therapeutic use, Adenosine therapeutic use, Coronary Circulation drug effects, Coronary Occlusion diagnosis, Coronary Occlusion surgery, Myocardial Infarction diagnosis, Myocardial Infarction etiology, Myocardial Infarction therapy, No-Reflow Phenomenon diagnosis, No-Reflow Phenomenon etiology, No-Reflow Phenomenon therapy, Percutaneous Coronary Intervention adverse effects, Percutaneous Coronary Intervention methods, Postoperative Complications etiology, Postoperative Complications physiopathology, Postoperative Complications therapy
Abstract

Objectives: To assess the incidence of no-reflow in patients undergoing chronic total occlusion (CTO) percutaneous coronary intervention (PCI), analyze possible causes and differential diagnoses, and identify useful management approaches., Methods: In this multicenter observational study, all CTO-PCIs performed between January 2018 and April 2019 were reviewed to collect no-reflow complications, defined as Thrombolysis in Myocardial Infarction (TIMI) flow ≤1 in a patent epicardial artery. Patient clinical, anatomical, and procedural characteristics were analyzed., Results: Out of 461 PCIs, two (0.43%) were complicated by no-reflow. In 1 case, PCI was performed on a long segment of the right coronary artery, after use of a dissection-re-entry technique by knuckle wiring. In the second patient, no-reflow developed after proximal left anterior descending coronary artery stenting, with a short subintimal tracking. Intravascular ultrasound was used to exclude complications in the epicardial vessel in both cases. Distal embolization seems the most plausible cause, and intracoronary adenosine effectively improved flow. Both patients had a type 4a myocardial infarction, asymptomatic in the first case, and associated with chest pain, electrocardiographic changes, and new regional wall-motion abnormality at echocardiography in the second case., Conclusions: No-reflow in CTO recanalization is rare, but associated with a high risk of periprocedural myocardial infarction, with incomplete protection from ischemia offered by the pre-existing collateral network.

Published
2020
Full Text
View/download PDF

33. [Updated SICI-GISE position paper on institutional and operator requirements for transcatheter aortic valve implantation].

Author

Tarantini G, Esposito G, Musumeci G, Fraccaro C, Franzone A, Castiglioni B, La Manna A, Limbruno U, Marchese A, Mauro C, Rigattieri S, Tarantino F, Gandolfo C, Santoro G, Violini R, Airoldi F, Albiero R, Balbi M, Baralis G, Bartorelli AL, Bedogni F, Benassi A, Berni A, Bonzani G, Bortone AS, Braito G, Briguori C, Brscic E, Calabrò P, Calchera I, Cappelli Bigazzi M, Caprioglio F, Castriota F, Cernetti C, Cicala C, Cioffi P, Colombo A, Colombo V, Contegiacomo G, Cremonesi A, D'Amico M, De Benedictis M, De Leo A, Di Biasi M, Di Girolamo D, Di Lorenzo E, Di Mario C, Dominici M, Ettori F, Ferrario M, Fioranelli M, Fischetti D, Gabrielli G, Giordano A, Giudice P, Greco C, Indolfi C, Leonzi O, Lettieri C, Loi B, Maddestra N, Marchionni N, Marrozzini C, Medda M, Missiroli B, My L, Oreglia JA, Palmieri C, Pantaleo P, Paparoni SR, Parodi G, Petronio AS, Piatti L, Piccaluga E, Pierli C, Perkan A, Pitì A, Poli A, Ramondo AB, Reale MA, Reimers B, Ribichini FL, Rosso R, Saccà S, Sacra C, Santarelli A, Sardella G, Satullo G, Scalise F, Siviglia M, Spedicato L, Stabile A, Tamburino C, Tesorio TNM, Tolaro S, Tomai F, Trani C, Valenti R, Valsecchi O, Valva G, Varbella F, Vigna C, Vignali L, and Berti S

Subjects
Aortic Valve Stenosis physiopathology, Biomedical Technology trends, Humans, Italy, Severity of Illness Index, Transcatheter Aortic Valve Replacement instrumentation, Aortic Valve Stenosis surgery, Program Development methods, Transcatheter Aortic Valve Replacement methods
Abstract

Transcatheter aortic valve implantation (TAVI) has revolutionized the management of patients with symptomatic severe aortic stenosis and has become the standard of care for inoperable patients and the preferred therapy for those at increased surgical risk with peculiar clinical and anatomic features. Technology advances, growing experience and accumulating data prompted the update of the 2011 Italian Society of Interventional Cardiology (SICI-GISE) position paper on institutional and operator requirements to perform TAVI. The main objective of this document is to provide a guidance to assess the potential of institutions and operators to initiate and maintain an efficient TAVI program.

Published
2018
Full Text
View/download PDF

34. [ANMCO/AIAC/SICI-GISE/SIC/SICCH Consensus document: Percutaneous left atrial appendage occlusion in patients with nonvalvular atrial fibrillation: indications, patient selection, competences, organization, and operator training].

Author

Casu G, Gulizia MM, Molon G, Mazzone P, Audo A, Casolo G, Di Lorenzo E, Portoghese M, Pristipino C, Ricci RP, Themistoclakis S, Padeletti L, Tondo C, Berti S, Oreglia JA, Gerosa G, Zanobini M, Ussia GP, Musumeci G, Romeo F, and Di Bartolomeo R

Subjects
Administration, Oral, Atrial Fibrillation complications, Humans, Patient Selection, Risk Factors, Septal Occluder Device, Stroke etiology, Anticoagulants administration & dosage, Atrial Appendage surgery, Atrial Fibrillation therapy, Catheter Ablation, Fibrinolytic Agents administration & dosage, Stroke prevention & control, Thrombosis therapy
Abstract

Atrial fibrillation (AF) is the most common arrhythmia and its prevalence is increasing due to the progressive aging of the population. About 20% of strokes are attributable to AF and AF patients are at 5-fold increased risk of stroke. The mainstay of treatment of AF is the prevention of thromboembolic complications with oral anticoagulation therapy. Drug treatment for many years has been based on the use of vitamin K antagonists, but recently newer and safer molecules have been introduced (dabigatran etexilate, rivaroxaban, apixaban and edoxaban). Despite these advances, many patients still do not receive adequate anticoagulation therapy because of contraindications (relative and absolute) to this treatment. Over the last decade, percutaneous closure of left atrial appendage, main site of thrombus formation during AF, proved effective in reducing thromboembolic complications, thus offering a valid medical treatment especially in patients at increased bleeding risk. The aim of this consensus document is to review the main aspects of left atrial appendage occlusion (selection and multidisciplinary assessment of patients, currently available methods and devices, requirements for centers and operators, associated therapies and follow-up modalities) having as a ground the significant evolution of techniques and the available relevant clinical data.

Published
2016
Full Text
View/download PDF

35. [The conundrum of therapeutic management in acute myocardial infarction complicated by endoventricular thrombosis: moving between different risks].

Author

Varrenti M, Morici N, De Chiara B, Oreglia JA, Pedrotti P, Giannattasio C, Klugmann S, and Roghi A

Subjects
Adult, Anterior Wall Myocardial Infarction physiopathology, Anticoagulants therapeutic use, Echocardiography, Edema etiology, Edema pathology, Humans, Magnetic Resonance Imaging, Male, Thrombosis complications, Thrombosis diagnosis, Anterior Wall Myocardial Infarction therapy, Heart Ventricles pathology, Thrombosis pathology
Abstract

Coronary artery disease is a rare entity in young patients and accurate assessment of its prevalence is difficult. Although coronary artery disease is frequently a silent process, it may also acutely present with myocardial infarction (MI). One of the most feared complications of MI is left ventricular thrombus formation. Transthoracic echocardiography is recommended for all patients with MI, and cardiac magnetic resonance should be considered because of its higher sensitivity if thrombus cannot clearly be demonstrated. The optimal treatment is based on anticoagulant therapy that should be started early and maintained for 3-4 months after the index event. We report the case of a 35-year-old male patient with anterior MI, complicated by left ventricular thrombus formation, extensive edema, microvascular obstruction and hemorrhagic core of the apical septum on cardiac magnetic resonance assessment.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results